Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Chronic HBV infection is a risk factor for BTC, potentially affecting the effectiveness of BTC treatment. In this study, treatment outcomes in participants who received first-line pembrolizumab plus gemcitabine and cisplatin for advanced BTC treatment were consistent regardless of HBV infection status.

Authors

Institutions

Publication Details

Journal
Cancer Research Communications
Published
2026-02-27
DOI
https://doi.org/10.1158/2767-9764.crc-25-0633
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

M. Ozaka, A. Vogel, Liis Starkopf, R. K. Kelley et al.
Cancer Research Communications
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

M. Ozaka, A. Vogel, Liis Starkopf, R. K. Kelley, Julien Edeline, Richard S. Finn, Ren Zheng-gang, Juan Valle, Uwe Pelzer, Heinz-Josef Klümpen, Shukui Qin, Abby B. Siegel, Changhoon Yoo, M. Ueno, Stephen Lam Chan, Usha Malhotra, Junji Furuse, Joon Oh Park, Thomas Yau, Cagatay Arslan
article en

Abstract

Chronic HBV infection is a risk factor for BTC, potentially affecting the effectiveness of BTC treatment. In this study, treatment outcomes in participants who received first-line pembrolizumab plus gemcitabine and cisplatin for advanced BTC treatment were consistent regardless of HBV infection status.

Cancer Research CommunicationsVol. 6(3)
Ulsan College (KR), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), University Medical Center Groningen (NL), University of California, Los Angeles (US), China Pharmaceutical University (CN), Chinese University of Hong Kong (HK), University of California, San Francisco (US), Fudan University (CN), Asan Medical Center (KR), Samsung Medical Center (KR), Princess Margaret Cancer Centre (CA), University of Manchester (GB), Kanagawa Prefectural Hospital Organization (JP), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), University of Ulsan (KR), Education University of Hong Kong (HK), Centre Eugène Marquis (FR), Zhongshan Hospital (CN), Cancer Research UK Manchester Institute (GB), Kyorin University Hospital (JP), Cholangiocarcinoma Foundation (US), Japanese Foundation For Cancer Research (JP), Pamukkale University (TR), University of San Francisco (US), Sungkyunkwan University (KR), University of Hong Kong (HK)
Good health and well-being
Openalex Percentile: Top 41%
Cholangiocarcinoma and Gallbladder Cancer Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.